skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Palliative treatment of malignant ascites: profile of catumaxomab

Review

(3989) Views  (1145) Full article downloads

Authors: Lila Ammouri, Eric E Prommer

Published Date May 2010 Volume 2010:4 Pages 103 - 110
DOI: http://dx.doi.org/10.2147/BTT.S6697

Lila Ammouri, Eric E Prommer

Mayo Clinic Hospice and Palliative Medicine Program, Mayo Clinic College of Medicine, Mayo Clinic Hospital, Scottsdale, AZ, USA

Abstract: Malignant ascites is the abnormal accumulation of fluid in the peritoneal cavity associated with several intrapelvic and intra-abdominal malignancies. The development of ascites leads to significant symptoms and poor quality of life for the cancer patient. Available therapies for palliation include treatment of the underlying disease, but when there are no treatment options, the use of diuretics, implantation of drainage catheters, and surgical shunting techniques are considered. None of these symptom palliation options affect the course of disease. The development of trifunctional antibodies, which attach to specific overexpressed surface markers on tumor cells, and trigger an immune response leading to cytoreductive effects, represents a new approach to the management of malignant ascites. The purpose of this review is to highlight current therapies for malignant ascites and review data as to the effectiveness of a new trifunctional antibody, catumaxomab.

Keywords: catumaxomab, ascites, trifunctional






 

Other articles by Dr Eric Prommer



Readers of this article also read:

Therapeutic vaccines for malignant brain tumors
Safety of etanercept in elderly subjects with rheumatoid arthritis
Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model
Hepatitis B virus and Homo sapiens proteomewide analysis: A profusion of viral peptide overlaps in neuron-specific human proteins
Potential role of ustekinumab in the treatment of chronic plaque psoriasis
Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
New and emerging treatment approaches to lupus
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed